WO2018178936A1 - Radiolabeled biomolecules and their use - Google Patents
Radiolabeled biomolecules and their use Download PDFInfo
- Publication number
- WO2018178936A1 WO2018178936A1 PCT/IB2018/052211 IB2018052211W WO2018178936A1 WO 2018178936 A1 WO2018178936 A1 WO 2018178936A1 IB 2018052211 W IB2018052211 W IB 2018052211W WO 2018178936 A1 WO2018178936 A1 WO 2018178936A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- biomolecule
- vhh
- radiolabeled
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C*CN1CCN(CC(O)=O)CCN(C[*-])CCN(C[*-])CC1 Chemical compound C*CN1CCN(CC(O)=O)CCN(C[*-])CCN(C[*-])CC1 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- a metabolizable spacer or cleavable linker L 2 (e.g., a Brush Border enzyme cleavable linker), is located between CG and the aromatic ring.
- L 2 e.g., a Brush Border enzyme cleavable linker
- solvates covers any pharmaceutically acceptable solvates that the compounds of Formula 1, and 2, as well as the salts thereof, are able to form.
- Such solvates are, for example, hydrates, alcoholates, e.g., ethanolates, propanolates, and the like, especially hydrates.
- the radiolabeled biomolecules of the invention can be targeted to any diseased or malignant cell population. In some instances, it may be preferred to use small biomolecules.
- Brain metastases are cancer cells that have spread to the brain from primary tumors in other organs in the body. Metastatic tumors are among the most common mass lesions in the brain. An estimated 24-45% of all cancer patients have brain metastases. Lung, breast, melanoma, colon, and kidney cancers commonly spread to the brain. Brain metastases are associated with poor survival and high morbidity. Improving therapies for metastatic brain tumors is an aspect of the present invention.
- the radiolabeled biomolecules and the one or more therapeutic antibodies or therapeutic antibody fragments may be infused at the same time, or the infusions may be overlapping in time.
- the two drugs may be formulated together in one single pharmaceutical preparation, or they may be mixed together immediately before administration from two different pharmaceutical preparations, for example by dissolving or diluting into one single infusion solution.
- the two drugs are administered separately, i.e. , as two independent pharmaceutical compositions.
- a cytokine stimulating proliferation of leukocytes may be applied to ameliorate the effects of leukopenia or neutropenia.
- Embodiment 10 The compound of Embodiment 9, wherein the compound is N-succinimidyl 3- guanidinomethyl-5-[ 131 I]iodobenzoate, or N-succinimidyl 3-[ 2n At]astato-5-guanidinomethyl benzoate.
- Embodiment 31 The radiolabeled biomolecule or intermediate of Embodiment 30, wherein said VHH comprises an amino acid sequence selected from the sequences set forth in SEQ ID NOs: 1 -5.
- a molecule containing the guanidine -bearing amino acid arginine, Brush Border enzyme-cleavable linker dipeptide GlyTyr, and connected to the SIB moiety via a PEG linker (Arg-Gly-Tyr-PEG-SIB), is shown below in Schemes 4-6.
- the radiolabeled version of this molecule for example, Arg-Gly-Tyr-PEG- [ 131 I]SIB, is obtained from the corresponding tin precursor using a standard iododestannylation reaction.
- VHH protein in 0.5 M sodium phosphate buffer, pH 7.4 is reacted with 15 equivalents each of sodium iodide and chloramine-T at room temperature for 5-10 min.
- the reaction is quenched by the addition of sodium bisulphite (2 molar equivalent of chloramine-T).
- the iodinated protein is purified by gel filtration or ultra-filtration.
- VHHs in both monomeric and multimeric format currently are undergoing clinical evaluation as therapeutics for a number of diseases including inflammation.
- a panel of anti-HER2 VHHs have been labeled with a variety of radionuclides including 99m Tc, 68 Ga, 18 F, 131 I, and 177 Lu. These radiolabeled VHHs exhibited peak tumor uptake in the range of 3-6% ID/g and rapid clearance from all normal tissues except kidneys.
- the present invention provides more potent radiolabeled biomolecules that will exhibit significantly higher tumor uptake, lower accumulation in normal tissues including the kidneys, improved radiolabeling efficiency, and are for use in targeting internalizing receptors such as HER2 and HER1.
- the anti-HER2 5F7 VHH molecule was obtained as a gift from Ablynx NV (Ghent, Belgium), was selected from phage libraries derived from llamas that had been immunized with SKBR3 human breast carcinoma cells. Its production, purification and characterization were as described previously (see Pruszynski M, Koumarianou E, Vaidyanathan G, Revets H, Devoogdt N, Lahoutte T, et al. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
- the residual radioactivity was reconstituted in the HPLC mobile phase (200 ⁇ ) and injected onto a normal phase column. Procedures for isolation and deprotection were as described below for [ 211 At]SAGMB and iso- [ 211 At]SAGMB.
- immunoreactive fractions of the labeled 5F7 VHH conjugates were determined by the Lindmo method using magnetic beads coated with HER2 extracellular domain, or as a negative control, bovine serum albumin (BSA). Briefly, aliquots of labeled 5F7 ( ⁇ 5 ng) were incubated with doubling concentrations of both HER2- and BSA-coated beads, and the immunoreactive fraction was calculated as the specific binding extrapolated to infinite HER2 excess.
- BSA bovine serum albumin
- BT474M1 breast carcinoma cells were plated in 24-well plates at a density of 8 x 10 4 cells/well and incubated at 37°C for 24 h. The cells were then allowed to acclimatize at 4°C for 30 min prior to the addition of increasing concentrations of radiolabeled 5F7 conjugates (0.1-100 nM). Cells were then incubated at 4°C for 2 h, the medium containing unbound radioactivity was removed, and the cells were washed twice with cold PBS. Finally, the cells were solubilized by treatment with IN NaOH (0.5 mL) at 37°C for 10 min. Cell-associated radioactivity was counted using an automated gamma counter.
- 211 At has many potential advantages for targeted radiotherapy, the combination of the short tissue range of its ⁇ -particles and its 7.2-h half-life necessitates the development of strategies for rapidly achieving homogeneous and prolonged delivery to cancer cells with rapid clearance from normal tissues. Most approaches for achieving this goal utilize a small molecule such as a mAb fragment; however, unlike the case with whole mAbs, 211 At -labeled mAb fragments exhibit high uptake in thyroid and stomach, indicating release of free 211 At in vivo.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019553023A JP2020512348A (ja) | 2017-03-30 | 2018-03-29 | 放射標識生体分子およびその使用 |
| US16/498,264 US20200188541A1 (en) | 2017-03-30 | 2018-03-29 | Radiolabeled biomolecules and their use |
| CN201880036082.1A CN110709106A (zh) | 2017-03-30 | 2018-03-29 | 放射性标记的生物分子及其应用 |
| EP18718637.4A EP3600453A1 (en) | 2017-03-30 | 2018-03-29 | Radiolabeled biomolecules and their use |
| JP2023062556A JP2023076712A (ja) | 2017-03-30 | 2023-04-07 | 放射標識生体分子およびその使用 |
| US18/946,772 US20250073359A1 (en) | 2017-03-30 | 2024-11-13 | Radiolabeled biomolecules and their use |
| JP2025027120A JP2025071280A (ja) | 2017-03-30 | 2025-02-21 | 放射標識生体分子およびその使用 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478754P | 2017-03-30 | 2017-03-30 | |
| US62/478,754 | 2017-03-30 | ||
| US201762500692P | 2017-05-03 | 2017-05-03 | |
| US62/500,692 | 2017-05-03 | ||
| US201762529532P | 2017-07-07 | 2017-07-07 | |
| US62/529,532 | 2017-07-07 | ||
| US201762583134P | 2017-11-08 | 2017-11-08 | |
| US62/583,134 | 2017-11-08 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/498,264 A-371-Of-International US20200188541A1 (en) | 2017-03-30 | 2018-03-29 | Radiolabeled biomolecules and their use |
| US18/946,772 Division US20250073359A1 (en) | 2017-03-30 | 2024-11-13 | Radiolabeled biomolecules and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018178936A1 true WO2018178936A1 (en) | 2018-10-04 |
Family
ID=62017598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2018/052211 Ceased WO2018178936A1 (en) | 2017-03-30 | 2018-03-29 | Radiolabeled biomolecules and their use |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200188541A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3600453A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2020512348A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110709106A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018178936A1 (cg-RX-API-DMAC7.html) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020242948A1 (en) | 2019-05-24 | 2020-12-03 | Duke University | 18f-radiolabeled biomolecules |
| WO2021096968A1 (en) | 2019-11-13 | 2021-05-20 | Duke University | Radiohalogen prosthetic moieties and radiolabeled biomolecules |
| JP2023541892A (ja) * | 2020-09-11 | 2023-10-04 | プレシリックス・ナームローゼ・ベンノートシヤープ | 固相により推進される放射性化合物の反応 |
| WO2023230488A1 (en) | 2022-05-23 | 2023-11-30 | Cereius, Inc. | Her2-binding agents and uses thereof |
| US20240358867A1 (en) * | 2021-09-01 | 2024-10-31 | Duke University | Reagents for site-specific labeling of proteins with radiohalogens, and methods of making and using the same |
| WO2026128025A2 (en) | 2024-07-03 | 2026-06-18 | Solve Therapeutics, Inc. | Anti-ror2 antibody-radionuclide conjugates |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4337265A4 (en) * | 2021-05-14 | 2026-03-25 | Purdue Research Foundation | TARGETED FOLATE RECEPTOR CONJUGATIONS WITH BRUSH-ON ENZYME-CLEVABLE BINDERS AND METHODS OF USE IN CANCER IMAGING AND TREATMENT |
| CN118388451A (zh) * | 2024-06-28 | 2024-07-26 | 四川大学 | 一种放射性标记的成纤维细胞活化蛋白抑制剂及其制备方法和应用 |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5302700A (en) | 1988-05-23 | 1994-04-12 | Duke University | Radiohalogenation conjugate technology |
| US6248516B1 (en) | 1988-11-11 | 2001-06-19 | Medical Research Council | Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors |
| US6300064B1 (en) | 1995-08-18 | 2001-10-09 | Morphosys Ag | Protein/(poly)peptide libraries |
| US6696245B2 (en) | 1997-10-20 | 2004-02-24 | Domantis Limited | Methods for selecting functional polypeptides |
| WO2007120251A2 (en) * | 2005-12-22 | 2007-10-25 | Duke University | Stabilized compositions and methods for radiolabeling pharmaceuticals with alpha-particle emitters |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| US8524244B2 (en) | 2008-02-14 | 2013-09-03 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
| WO2014179715A1 (en) * | 2013-05-02 | 2014-11-06 | Duke University | Prosthetic compounds for labeling internalizing biomolecules |
| US9234065B2 (en) | 2011-01-12 | 2016-01-12 | Mitsubishi Rayon Co., Ltd. | Active energy ray-curable resin composition, product having the uneven microstructure, and method for producing product having the uneven microstructure |
| US9243065B2 (en) | 2002-11-08 | 2016-01-26 | Ablynx N.V. | Polypeptide constructs including VHH directed against EGFR for intracellular delivery |
| WO2016016021A1 (en) * | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer |
| US9309515B2 (en) | 2011-06-24 | 2016-04-12 | Postech Academy-Industry Foundation | Aptamer which selectively binds to ERBB2 receptor and uses thereof |
-
2018
- 2018-03-29 JP JP2019553023A patent/JP2020512348A/ja not_active Withdrawn
- 2018-03-29 EP EP18718637.4A patent/EP3600453A1/en active Pending
- 2018-03-29 CN CN201880036082.1A patent/CN110709106A/zh active Pending
- 2018-03-29 US US16/498,264 patent/US20200188541A1/en not_active Abandoned
- 2018-03-29 WO PCT/IB2018/052211 patent/WO2018178936A1/en not_active Ceased
-
2023
- 2023-04-07 JP JP2023062556A patent/JP2023076712A/ja not_active Withdrawn
-
2024
- 2024-11-13 US US18/946,772 patent/US20250073359A1/en active Pending
-
2025
- 2025-02-21 JP JP2025027120A patent/JP2025071280A/ja active Pending
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5302700A (en) | 1988-05-23 | 1994-04-12 | Duke University | Radiohalogenation conjugate technology |
| US6248516B1 (en) | 1988-11-11 | 2001-06-19 | Medical Research Council | Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors |
| US6300064B1 (en) | 1995-08-18 | 2001-10-09 | Morphosys Ag | Protein/(poly)peptide libraries |
| US6696245B2 (en) | 1997-10-20 | 2004-02-24 | Domantis Limited | Methods for selecting functional polypeptides |
| US6846634B1 (en) | 1997-10-20 | 2005-01-25 | Domantis Limited | Method to screen phage display libraries with different ligands |
| US9243065B2 (en) | 2002-11-08 | 2016-01-26 | Ablynx N.V. | Polypeptide constructs including VHH directed against EGFR for intracellular delivery |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| WO2007120251A2 (en) * | 2005-12-22 | 2007-10-25 | Duke University | Stabilized compositions and methods for radiolabeling pharmaceuticals with alpha-particle emitters |
| US9234028B2 (en) | 2008-02-14 | 2016-01-12 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
| US8524244B2 (en) | 2008-02-14 | 2013-09-03 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
| US9234065B2 (en) | 2011-01-12 | 2016-01-12 | Mitsubishi Rayon Co., Ltd. | Active energy ray-curable resin composition, product having the uneven microstructure, and method for producing product having the uneven microstructure |
| US9309515B2 (en) | 2011-06-24 | 2016-04-12 | Postech Academy-Industry Foundation | Aptamer which selectively binds to ERBB2 receptor and uses thereof |
| WO2014179715A1 (en) * | 2013-05-02 | 2014-11-06 | Duke University | Prosthetic compounds for labeling internalizing biomolecules |
| WO2016016021A1 (en) * | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer |
Non-Patent Citations (30)
| Title |
|---|
| AKIZAWA ET AL., BIOCONJUGATE CHEM, vol. 24, 2013, pages 291 - 299 |
| ARANO ET AL., CANCER RESEARCH, vol. 59, 1999, pages 128 - 134 |
| BRADWELL ET AL., IMMUNOLOGY TODAY, vol. 6, 1985, pages 163 - 170 |
| CHOI ET AL., NUCL MED BIOL, vol. 41, no. 10, 2014, pages 802 - 812 |
| CHOI ET AL., NUCL MED BIOL, vol. 41, no. 10, 2014, pages 802 - 812, XP055312538 * |
| CHOI J. ET AL., NUCL MED BIOL, vol. 41, 2014, pages 802 - 12 |
| CHOI J; VAIDYANATHAN G; KOUMARIANOU E; MCDOUGALD D; PRUSZYNSKI M; OSADA T ET AL.: "N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization", NUCL MED BIOL, vol. 41, 2014, pages 802 - 12, XP055312538, DOI: doi:10.1016/j.nucmedbio.2014.07.005 |
| ELLINGTON; SZOSTAK, NATURE, vol. 346, 1990, pages 818 - 822 |
| GALI ET AL., ANTICANCER RESEARCH, vol. 21, no. 4A, 2001, pages 2785 - 2792 |
| GIJS ET AL., PHARMACEUTICALS (BASEL, vol. 9, no. 2, 2016, pages 29 |
| JODAL ET AL., PLOS ONE, vol. 10, no. 4, 9 April 2015 (2015-04-09), pages e0123443 |
| KEEFE ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 9, 2010, pages 537 - 550 |
| KULBACHINSKIY, A. V., BIOCHEMISTRY, vol. 72, 2007, pages 1505 - 1518 |
| LI ET AL., BIOCONJUG CHEM, vol. 13, no. 5, 2002, pages 985 - 995 |
| LIU ET AL., J TRANSL. MED., vol. 10, 2012, pages 148 |
| MAHLKNECHT ET AL., PROC. NATL. ACAD. SCI., vol. 110, 2012, pages 8170 - 8175 |
| MITTAPALI ET AL., CANCER RES, vol. 77, no. 2, 2017, pages 238 - 246 |
| MOOSAVIAN ET AL., IRAN J. BASIC MED. SCI., vol. 18, no. 6, 2015, pages 576 - 586 |
| PRUSZYNSKI M; KOUMARIANOU E; VAIDYANATHAN G; REVETS H; DEVOOGDT N; LAHOUTTE T ET AL.: "Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling", J NUCL MED, vol. 55, 2014, pages 650 - 6, XP055180992 * |
| PRUSZYNSKI M; KOUMARIANOU E; VAIDYANATHAN G; REVETS H; DEVOOGDT N; LAHOUTTE T ET AL.: "Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling", J NUCL MED, vol. 55, 2014, pages 650 - 6, XP055180992, DOI: doi:10.2967/jnumed.113.127100 |
| PRUSZYNSKI M; KOUMARIANOU E; VAIDYANATHAN G; REVETS H; DEVOOGDT N; LAHOUTTE T ET AL.: "Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody", NUCL MED BIOL, vol. 40, 2013, pages 52 - 9, XP055312393, DOI: doi:10.1016/j.nucmedbio.2012.08.008 |
| REIST ET AL., NUCL MED BIOL, vol. 24, no. 7, 1997, pages 639 - 648 |
| STEIN ET AL., CANCER RES, vol. 63, 2003, pages 111 - 118 |
| THOMPSON ET AL., NUCLEIC ACIDS RES, vol. 22, 1994, pages 4673 - 4680 |
| TUERK; GOLD, SCIENCE, vol. 249, 1990, pages 505 - 510 |
| VAIDYANATHAN ET AL., BIOORG. MED. CHEM., vol. 20, no. 24, 2012, pages 6929 - 6939 |
| VAIDYANATHAN G; MCDOUGALD D; CHOI J.; KOUMARIANOU E; WEITZEL D; OSADA T ET AL.: "Preclinical evaluation of F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET", J NUCL MED, vol. 57, 2016, pages 967 - 73 |
| VAIDYANATHAN G; ZALUTSKY MR: "Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides", NATURE PROT, vol. 2, 2007, pages 282 - 6, XP009133348 |
| XAVIER C; VANEYCKEN I; D'HUYVETTER M; HEEMSKERK J; KEYAERTS M; VINCKE C ET AL.: "Synthesis, preclinical validation, dosimetry, and toxicity of Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer", J NUCL MED, vol. 54, 2013, pages 776 - 784, XP055181016 * |
| XAVIER C; VANEYCKEN I; D'HUYVETTER M; HEEMSKERK J; KEYAERTS M; VINCKE C ET AL.: "Synthesis, preclinical validation, dosimetry, and toxicity of Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer", J NUCL MED, vol. 54, 2013, pages 776 - 784, XP055181016, DOI: doi:10.2967/jnumed.112.111021 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020242948A1 (en) | 2019-05-24 | 2020-12-03 | Duke University | 18f-radiolabeled biomolecules |
| AU2020283822B2 (en) * | 2019-05-24 | 2026-01-08 | Duke University | 18F-radiolabeled biomolecules |
| WO2021096968A1 (en) | 2019-11-13 | 2021-05-20 | Duke University | Radiohalogen prosthetic moieties and radiolabeled biomolecules |
| JP2023501579A (ja) * | 2019-11-13 | 2023-01-18 | デューク ユニバーシティ | 放射性ハロゲン補欠部分および放射標識生体分子 |
| JP7774308B2 (ja) | 2019-11-13 | 2025-11-21 | デューク ユニバーシティ | 放射性ハロゲン補欠部分および放射標識生体分子 |
| US12637398B2 (en) | 2019-11-13 | 2026-05-26 | Duke University | Radiohalogen prosthetic moieties and radiolabeled biomolecules |
| JP2023541892A (ja) * | 2020-09-11 | 2023-10-04 | プレシリックス・ナームローゼ・ベンノートシヤープ | 固相により推進される放射性化合物の反応 |
| US20240358867A1 (en) * | 2021-09-01 | 2024-10-31 | Duke University | Reagents for site-specific labeling of proteins with radiohalogens, and methods of making and using the same |
| WO2023230488A1 (en) | 2022-05-23 | 2023-11-30 | Cereius, Inc. | Her2-binding agents and uses thereof |
| WO2026128025A2 (en) | 2024-07-03 | 2026-06-18 | Solve Therapeutics, Inc. | Anti-ror2 antibody-radionuclide conjugates |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200188541A1 (en) | 2020-06-18 |
| JP2020512348A (ja) | 2020-04-23 |
| US20250073359A1 (en) | 2025-03-06 |
| EP3600453A1 (en) | 2020-02-05 |
| JP2023076712A (ja) | 2023-06-01 |
| CN110709106A (zh) | 2020-01-17 |
| JP2025071280A (ja) | 2025-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250073359A1 (en) | Radiolabeled biomolecules and their use | |
| Choi et al. | Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation | |
| JP6219372B2 (ja) | 放射性医薬錯体 | |
| Smith-Jones et al. | Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA–MORAb-003 | |
| JP5855209B2 (ja) | 放射免疫コンジュゲートおよびその使用 | |
| MD3548515T2 (ro) | Anticorpi anti-PD-L1 radiomarcați pentru imagistica imuno-PET | |
| US20230340111A1 (en) | Antibody fragment against folr1 | |
| WO2022174809A1 (en) | Anti-cldn18.2 antibody conjugates | |
| US20230381350A1 (en) | Antibody fragment against fap | |
| KR20170032463A (ko) | 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편 | |
| Suzuki et al. | Reduction of the renal radioactivity of 111In-DOTA-labeled antibody fragments with a linkage cleaved by the renal brush border membrane enzymes | |
| Warnders et al. | Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non‐Ig scaffolds | |
| Nakashima et al. | Development of novel trifunctional chelating agents that enhance tumor retention of radioimmunoconjugates | |
| JP2024530057A (ja) | ネトリン-1検出、コンパニオン検査及び放射線に基づく療法 | |
| EP4317188A1 (en) | Radioactive complex of anti-egfr antibody, and radiopharmaceutical | |
| EP4327831A1 (en) | Radioactive complex of anti-cd20 antibody, and radiopharmaceutical | |
| WO2026083399A1 (en) | Conjugates and use of same for theranostics | |
| Sarrami | Development of immuno and nano PET/SPECT probes: towards novel theranostics for EGFR positive solid tumors | |
| CA3285616A1 (en) | Method for producing radiolabeled antibody, radiolabeled antibody, and radiopharmaceutical | |
| WO2025247428A1 (zh) | 一种双功能性融合蛋白、放射性核素标记物及其应用 | |
| HK40106087A (en) | Anti-cldn18.2 antibody conjugates | |
| TW202607033A (zh) | 抗ror2抗體-放射性核種結合物 | |
| KR20220054232A (ko) | 짧은 peg 링커를 이용한 방사성 표지된 항체 컨쥬게이트를 포함하는 면역 영상화제 | |
| TW202400240A (zh) | 抗vegf抗體的放射性複合體及放射性醫藥 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18718637 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2019553023 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2018718637 Country of ref document: EP Effective date: 20191030 |